Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status:
Withdrawn
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This phase I/Ib trial will assess the dose, safety and side effects of the combination of the
cancer drugs afatinib (GILOTRIF®) and nivolumab (OPDIVO®) and to assess the anti-cancer
effects of this combination of drugs when used to treat patients with advanced head and neck
cancers that did not respond to previous treatments.
Phase:
Phase 1
Details
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborators:
Boehringer Ingelheim National Comprehensive Cancer Network